» Articles » PMID: 24272883

Epigenetic Regulation of MiRNA-cancer Stem Cells Nexus by Nutraceuticals

Overview
Date 2013 Nov 26
PMID 24272883
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Nutraceuticals, the bioactive food components represented by many naturally occurring dietary compounds, have been investigated for a few decades for their numerous beneficial effects, including their anticancer properties. The initial interest in the cancer-preventing/therapeutic ability of these agents was based on their ability to affect multiple signaling pathways that are deregulated in cancer cells. With a shift in the focus of cancer research to the emerging areas such as epigenetic regulation, microRNAs (miRNAs) and the cancer stem cells (CSCs), nutraceuticals initially appeared out of place. However, research investigations over the last several years have slowly but firmly presented evidence that supports a relevance of these agents in modern day research. While nutraceuticals are increasingly being realized to alter miRNA/CSCs expression and function, the molecular mechanism(s) are not very clearly understood. Epigenetic regulation is one mechanism by which these agents exert their anticancer effects. In this focused mini review, we summarize our current understanding of epigenetic regulation of miRNAs and CSCs by nutraceuticals. We discuss both direct and indirect evidences that support such an activity of these compounds.

Citing Articles

Role of a Polyphenol-Enriched Blueberry Preparation on Inhibition of Melanoma Cancer Stem Cells and Modulation of MicroRNAs.

Alsadi N, Yahfoufi N, Nessim C, Matar C Biomedicines. 2024; 12(1).

PMID: 38255297 PMC: 10813708. DOI: 10.3390/biomedicines12010193.


Ellagic acid modulates cisplatin toxicity in DMH induced colorectal cancer: Studies on membrane alterations.

Goyal Y, Koul A, Ranawat P Biochem Biophys Rep. 2022; 31:101319.

PMID: 35990576 PMC: 9386026. DOI: 10.1016/j.bbrep.2022.101319.


Epigenetic basis of cancer drug resistance.

Aziz M, Ahmad A Cancer Drug Resist. 2022; 3(1):113-116.

PMID: 35582041 PMC: 9094056. DOI: 10.20517/cdr.2020.06.


Epigenetic underpinnings of inflammation: Connecting the dots between pulmonary diseases, lung cancer and COVID-19.

Ahmad S, Manzoor S, Siddiqui S, Mariappan N, Zafar I, Ahmad A Semin Cancer Biol. 2021; 83:384-398.

PMID: 33484868 PMC: 8046427. DOI: 10.1016/j.semcancer.2021.01.003.


Epigenetic inactivation of miR-203 as a key step in neural crest epithelial-to-mesenchymal transition.

Sanchez-Vasquez E, Bronner M, Strobl-Mazzulla P Development. 2019; 146(7).

PMID: 30910825 PMC: 6467475. DOI: 10.1242/dev.171017.


References
1.
Grivennikov S, Karin M . Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev. 2009; 20(1):65-71. PMC: 2821983. DOI: 10.1016/j.gde.2009.11.004. View

2.
Feinberg A, Vogelstein B . Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature. 1983; 301(5895):89-92. DOI: 10.1038/301089a0. View

3.
Bourguignon L, Wong G, Earle C, Chen L . Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. J Biol Chem. 2012; 287(39):32800-24. PMC: 3463333. DOI: 10.1074/jbc.M111.308528. View

4.
Ahmad A, Biersack B, Li Y, Bao B, Kong D, Ali S . Perspectives on the role of isoflavones in prostate cancer. AAPS J. 2013; 15(4):991-1000. PMC: 3787218. DOI: 10.1208/s12248-013-9507-1. View

5.
Baylin S, Jones P . A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011; 11(10):726-34. PMC: 3307543. DOI: 10.1038/nrc3130. View